ImmunoMet Therapeutics, a clinical stage biotechnology company targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies, today announced its participation in the 2020 BIO CEO & Investor Conference, February 10-11, 2020, at the New York Marriott Marquis, New York, NY. Benjamin Cowen, PhD, MBA, ImmunoMet President and CEO will present a company overview and offer his industry expertise in an oncology-focused panel. Details noted below:

Panel: Expanding the Toolkit for Fighting Solid Tumors
February 10, 2020     9:00 AM – 9:55 AM ET
As PD-1/L1 checkpoint inhibitors continue to reveal new tumor types those drugs can attack successfully, more than 2,000 combination trials have launched to attempt to enhance those inhibitors’ effects. However, exciting approaches in other mechanisms of action are also expanding our understanding of solid tumors, the tumor microenvironments, and the opportunities to disrupt tumor growth and help cancer patients. This panel will explore the breadth of the tumor-fighting pipelines and those clinical benefits likely to be realized soonest.

 Company Presentation: Benjamin Cowen will present a company update.
February 10, 2020     2:15 PM – 2:30 PM ET

About BIO CEO & Investor Conference Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. The conference includes two days of productive partnering meetings with institutional investors, industry analysts and senior biotechnology executives, in one location.

 About ImmunoMet Therapeutics ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is a protein complex 1 (PC1) inhibitor which demonstrated impressive in-vivo efficacy in resistant solid tumors. IM156 is the first potent PC1 inhibitor to complete Phase 1 with a good safety profile. ImmunoMet has a second program in fibrosis and plans to enter the clinic with IM156 in 2H2020. The company was founded in 2015, is headquartered in the Houston JLABs near MD Anderson, and has raised $19M to date.